| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Peter McNamara | CSci | 2026-08-25 | 43 | $36.52 | $1.57kSell |
| Peter McNamara | CSci | 2026-08-25 | 43 | $14.71 | $632.53Buy |
| Peter McNamara | CSci | 2026-08-12 | 43 | $35.00 | $1.51kSell |
| Peter McNamara | CSci | 2026-08-12 | 43 | $14.71 | $632.53Buy |
| Peter McNamara | Chief Scientific Officer | 2026-06-30 | 172 | $35.00 | $6.02kSell |
| Peter McNamara | Chief Scientific Officer | 2026-06-30 | 172 | $14.71 | $2.53kBuy |
| Alise Reicin | Chief Executive Officer | 2026-06-20 | 924 | $30.34 | $28.03kSell |
| Marcella K. Ruddy | Chief Medical Officer | 2026-05-04 | 1,065 | $30.00 | $31.95kSell |
| Marcella K. Ruddy | Chief Medical Officer | 2026-04-01 | 1,000 | $31.05 | $31.05kSell |
| Peter McNamara | Chief Scientific Officer | 2026-03-06 | 215 | $35.00 | $7.53kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Timothy A. Springer | 30.82% | 6,024,338 | $168.14M | Insider |
| Bruce Booth | 28.48% | 5,567,289 | $155.38M | Insider |
| Braden Michael Leonard | 25.09% | 4,905,068 | $136.90M | Insider |
| Atlas Venture Fund X LP | 24.33% | 4,756,478 | $132.75M | Insider |
| Clarus Lifesciences III LP | 22.73% | 4,443,487 | $124.02M | Insider |
| Atlas Venture Associates X LP | 18.98% | 3,710,052 | $103.55M | Insider |
| Blackstone Holdings II LP | 15.15% | 2,962,325 | $82.68M | Insider |
| Scott Requadt | 15.15% | 2,962,325 | $82.68M | Insider |
| Atlas Venture Opportunity Fund I LP | 4.15% | 810,811 | $22.63M | Insider |
| Geoffrey MacKay | 3.98% | 778,343 | $21.72M | Insider |